Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSKN021 in Advanced Malignant Solid Tumors
NCT07617727Phase 1Recruiting
- Sponsor
- Alphamab Oncology
- Start
- Jun 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of JSKN021 in solid tumor (8 cohorts), sponsored by Alphamab Oncology. Primary endpoints: Adverse Events at 30 days, Dose-Limiting Toxicity at 21 days and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
JSKN021
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07617727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07617727.